Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

EVEREST MEDICINES
云 顶 新 耀

Everest Medicines Limited
雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY DIRECTORS AND SUBSTANTIAL SHAREHOLDER OF THE COMPANY

This announcement is made by Everest Medicines Limited (the "**Company**") on a voluntary basis.

The board (the "**Board**") of directors (the "**Directors**") of the Company announces that on 12 December 2025, Mr. Wei Fu (being a non-executive Director, the honorary chairman of the Board and a substantial shareholder of the Company), Mr. Yifang Wu (being an executive Director and the chairman of the Board), Mr. Yongqing Luo (being an executive Director and the chief executive officer of the Company), and Mr. Ian Ying Woo (being an executive Director, the president and chief financial officer of the Company), purchased 339,000, 277,000, 132,500 and 98,159 ordinary shares of the Company (the "**Shares**") respectively on the market for a total consideration exceeding HK$38,000,000, representing an average price of approximately HK$45.01 per Share.

The Company is informed that CBC Group, being a substantial shareholder of the Company, has further undertaken that it plans to increase its shareholding by not more than 1% in aggregate in the following three to six months, subject to the market conditions and compliance with applicable laws and regulatory requirements.

The Board believes that a voluntary share purchase through on-market acquisitions of Shares by the Directors and the undertaking given by CBC Group signify strong confidence in the future prospects and long-term development of the Company.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 15 December 2025

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.